|
The Effect Of Combination Of Octadecanoic Acid, Methyl Ester And Ribavirin Against Measles Virus
[Full Text]
AUTHOR(S)
Reagan Entigu Ak Linton @ Jerah, Samuel Lihan, Ismail bin Ahmad
KEYWORDS
Index terms: Antiviral, Cymbopogon nardus, cytotoxicity, measles, octadecanoic acid, methyl ester, ribavirin
ABSTRACT
Abstract: Ribavirin is a broad spectrum antiviral drug and has been used to treat various diseases. It has been used as a treatment for subacute sclerosis panencephalitis (SSPE) caused by measles virus infection. However, there were several adverse effects when receiving ribavirin treatment. Other than ribavirin and vaccine, there is no cure for the disease thus medicinal plants being studied for their potential active compounds to be used as either mono or combined treatment with drugs. The objective of this study was to test antiviral activity of octadecanoic acid, methyl ester (OA), extracted from Cymbopogon nardus (sweet lemon grass) against measles virus in both mono and combination with ribavirin. The cytotoxicity and antiviral activity were tested at low concentration for the compound (25, 12.5 and 2.5 µg/ml) and ribavirin (0.1, 0.05 and 0.01 CC50). The cytotoxicity result showed that the low concentrations of both compounds have low cytotoxicity on Vero cell although there was slight increment of toxicity when they were combined. However, the combined treatment showed higher antiviral activity (p <0.05) compared to single treatment of both compounds (OA12.5 µg/ml + RBV0.05CC50: 94.38 ± 1.5%, OA12.5 µg/ml: 67.09 ± 0.2%, RBV0.05CC50: 51.12 ± 2.1%). The result has also shown that decreasing of the concentration of the combination could still maintained the antiviral activity comparable to single treatment and less cytotoxicity toward Vero cell. This study has proven that OA can be combined with commercial drug such as ribavirin to produce higher antiviral activity at lower concentration for combination of both compounds.
REFERENCES
[1]. G.Z. Leu, T.Y. Lin, and J.T.A. Hsu, “Anti-HCV activities of selective polyunsaturated fatty acids,” Biochemical and Biophysical Research Communications, 318(1), 275–80, 2004.
[2]. J.D. Kettering, “Virology,” Essentials of Diagnostic Microbiology, L. A. Shimeld, ed., USA: Delmar Publishers, pp. 635-680, 1999.
[3]. WHO, “Measles,” From World Health Organization site: http://www.who.int/mediacentre/factsheets/fs286/en/. 2009.
[4]. Ministry of Health Malaysia, “Measles prevention and control in Malaysia,” Handbook for healthcare personnel. Available at http://www.dph.gov.my/cdc/vaccine%20preventable%20disease%20unit/Publications,IEC/MEASLES.pdf. 2004.
[5]. S.K. Trying, “Antiviral Agents, Vaccines and Immunotherapies,” New York: Marcel Dekker, 2005.
[6]. R.T. D' Aquila, “Antiviral treatment strategies,” Schaechter's Mechanisms of Microbial Disease, 4th ed., M. Schaechter, N. C. Engleberg, V. J. DiRita, and T. Dermody, eds., Philadelphia: Lippincott Williams & Wilkins, pp. 435-444, 2007.
[7]. J.D. Graci, and C.E. Cameron, “Quasispecies, error catastrophe and the antiviral activity of ribavirin,” Virology (298), 175-180, 2002.
[8]. N.M. Dixit, J.E. Layden-Almer, T.J. Layden, and A.S. Perelson, “Modelling how ribavirin improves interferon response rate in hepatitis C virus infection,” Nature , 432 (7019), 922–924, 2004.
[9]. H. Chiou, C. Liu, M.J. Buttrey, H. Ku, H. Liu, H. Kou, and Y. Lu, “Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers,” CHEST Journal , 128 (1), 263-272, 2005.
[10]. G.D. Schiff, W.L. Galanter, J. Duhig, M.J. Koronkowski, and A.E. Lodolce, “A prescription for improving drug formulary decision making,” Public Library of Science Medicine, 9(5): e1001220, 2012.
[11]. G. Renuka, V.S. Thiruvengadarajan, N. Amruthkumar, K. Mahesh and C. MadhusudhanChetty, “A review on herb-drug interactions,” International Journal of Pharmaceutical Research and Development, 3(3), Article 17, 2013.
[12]. Fugh-Berman, “Herb-drug interactions,” The Lancet, 355: 134-138, 2000.
[13]. M.B. Bolger, R. Fraczkiewicz, M. Entzeroth, and B. Steere, “Concepts for in-vitro profiling: Drug activity, selectivity and liability,” Exploiting Chemical Diversity for Drug Discovery, P. A. Barlett, and M. Entzeroth, eds., The Royal Society of Chemistry, pp. 336-360, 2006.
[14]. A.J. Vlientinck, T. De Bruyne, and D.A. Berghe, “Plant substances as antiviral agents,” Current Organic Chemistry, 1 (4), 307-344, 1997.
[15]. T. Takahashi, M. Hosoya, K. Kimura, K. Ohno, S. Mori, K. Takahashi, and S. Shigeta, ‘’The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in-vitro and in-vivo,” Antiviral Research, 37(1), 29–35, 1998.
[16]. Reagan, E., Samuel, L. & Ahmad, I. B., “Isolation of antiviral compound from Cymbopogon nardus methanolic fractions,” International Journal of Health and Pharmaceutical Sciences, 2(2), 1-7.
[17]. M. Chandrasekaran, A. Senthilkumar, and V. Venkatesalu, “Antibacterial and antifungal efficacy of fatty acid methyl esters from the leaves of Sesuvium portulacastrum L.,” European Review or Medical and Pharmacological Sciences, 15(7), 775–80, 2011.
[18]. F.R. Yu, X.Z. Lian, H.Y. Guo, P.M. McGuire, R.D. Li, R. Wang, and F.H. Yu, “Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells,” Journal of Pharmacy & Pharmaceutical Sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des Sciences Pharmaceutiques, 8(3), 528–35, 2005.
|
